Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

NCT01709487 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT01709487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01709487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
Lead sponsor
Jules Bordet Institute
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2010
Completion date
October 31, 2015
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma